AI for Respiratory Drug Discovery

Exscientia, an Oxford-based AI drug discovery company, applied its AI-driven platform to respiratory disease drug discovery. The company's automated systems and machine learning algorithms enabled rapid identification of optimized compounds for respiratory conditions. Exscientia's approach combined phenotypic screening with AI-driven design to generate novel compounds addressing unmet medical needs in respiratory diseases. The AI platform continuously learned from experimental data to improve compound predictions. In 2021, Exscientia announced a collaboration using their AI platform for virus protease inhibitor design, demonstrating broad applicability across respiratory and infectious diseases. Note: Exscientia merged with Recursion in 2024.